FDMT
4D Molecular Therapeutics, Inc.
There isn't enough reported data to score FDMT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
FDMT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
FDMT's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
FDMT PE Valuation
FDMT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
FDMT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect FDMT's losses to grow, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
FDMT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.70 | +$1.05 |
| Q2 2026 | -$2.63 | +$0.90 |
| Q1 2026 | -$2.57 | +$0.61 |
| Q4 2025 | -$2.42 | +$0.56 |
| Q3 2025 | -$3.75 | -$0.84 |
| Q2 2025 | -$3.53 | -$1.17 |
| Q1 2025 | -$3.18 | -$0.68 |
| Q4 2024 | -$2.98 | -$0.26 |
FDMT is still losing money, but far less than before: $2.70 per share over the past year, against $5.43 at its worst in late 2019.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
FDMT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.1M | +4506% |
| Q2 2026 | $3.8M | +25107% |
| Q1 2026 | $3M | +21664% |
| Q4 2025 | $85.1M | +8508900% |
| Q3 2025 | $90K | +2900% |
| Q2 2025 | $15K | +200% |
| Q1 2025 | $14K | -50% |
| Q3 2024 | $3K | -100% |
FDMT's revenue has grown year over year for six quarters in a row: $4M last quarter, up 4506% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1959% | +66024 points |
| Q2 2026 | -2037% | +394336 points |
| Q1 2026 | -2416% | +380591 points |
| Q4 2025 | 17% | +5611717 points |
| Q3 2025 | -67983% | +1636417 points |
| Q2 2025 | -396373% | +452747 points |
| Q1 2025 | -383007% | -246807 points |
| Q4 2024 | -5611700% | N/A |
FDMT's operating margin was −1959% last quarter, up 66024 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over FDMT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over FDMT on profitability, with a higher operating margin.
FDMT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$56.8M | -$10.4M |
| Q1 2026 | -$68.1M | -$19.7M |
| Q4 2025 | $28.6M | +$75.4M |
| Q3 2025 | -$46.4M | -$15.2M |
| Q2 2025 | -$43.4M | -$12.9M |
| Q1 2025 | -$48.4M | -$18.6M |
| Q4 2024 | -$46.8M | -$21.6M |
| Q3 2024 | -$31.2M | -$29.6M |
FDMT has the stronger cash trend. Its trailing FCF is down 44% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
FDMT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +2M shares |
| 1 year | +29% | +16.1M shares |
| 3 years | +71% | +30M shares |
| 5 years | +167% | +45.2M shares |
| Available history | +387% | +57.4M shares |
FDMT has 72M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over FDMT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
FDMT Net Leverage
FDMT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
FDMT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 31.2 | Neutral |
FDMT's weekly RSI is 51 (neutral) and its Stochastic is 31 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
FDMT PE vs Healthcare Sector
FDMT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
FDMT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.6 | 3.7% below |
| 20 week MA | $12.7 | 4.6% below |
| 50 week MA | $10.6 | 15% above |
| 100 week MA | $8.21 | 48% above |
| 200 week MA | $13.1 | 7.3% below |
FDMT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
FDMT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.5 | $40.0 | -1.2% |
| 2021 | $40.0 | $22.7 | -43% |
| 2022 | $22.7 | $21.6 | -5% |
| 2023 | $21.6 | $20.3 | -6.2% |
| 2024 | $20.3 | $5.55 | -73% |
| 2025 | $5.55 | $7.97 | +44% |
| 2026 YTD | $7.97 | $12.1 | +52% |
FDMT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.